BioCardia, Inc. (BCDA) Short-Term Debt to Capital

BioCardia, Inc. (BCDA) relies on external contractors for the creation of cell structures and the execution of tests, thereby avoiding the costs associated with maintaining its own facilities. Specialized cardiologists within the management team strictly control research expenditures to ensure data transparency. This price chart featuring the 0.10 metric confirms that the company is operating on legacy investments, as its commercial products are not yet generating profit.

The ratio of short-term liabilities to equity is used for primary risk screening, where changes in the share of short-term loans within equity help identify potential cash gaps and the threat of asset devaluation. For BioCardia, Inc. (BCDA), this balance is critical, as a high debt load could limit resources in the intensive race to develop cell therapy, despite patent protection.